Reply: Natriuretic Peptide-Based Risk Prediction and Assessment of Treatment Effect: Revisited in This Era

Free article

Comment

Francesco Gentile et al. JACC Heart Fail. 2021 Dec.

Free article

. 2021 Dec;9(12):942-943.

doi: 10.1016/j.jchf.2021.10.003.

No abstract available

Comment on

NT-proBNP for Risk Prediction in Heart Failure: Identification of Optimal Cutoffs Across Body Mass Index Categories.
Vergaro G, Gentile F, Meems LMG, Aimo A, Januzzi JL Jr, Richards AM, Lam CSP, Latini R, Staszewsky L, Anand IS, Cohn JN, Ueland T, Gullestad L, Aukrust P, Brunner-La Rocca HP, Bayes-Genis A, Lupón J, Yoshihisa A, Takeishi Y, Egstrup M, Gustafsson I, Gaggin HK, Eggers KM, Huber K, Gamble GD, Ling LH, Leong KTG, Yeo PSD, Ong HY, Jaufeerally F, Ng TP, Troughton R, Doughty RN, Devlin G, Lund M, Giannoni A, Passino C, de Boer RA, Emdin M. Vergaro G, et al. JACC Heart Fail. 2021 Sep;9(9):653-663. doi: 10.1016/j.jchf.2021.05.014. Epub 2021 Jul 7. JACC Heart Fail. 2021. PMID: 34246607
Natriuretic Peptide-Based Risk Prediction and Assessment of Treatment Effect: Revisited in This Era.
Tanaka A, Node K. Tanaka A, et al. JACC Heart Fail. 2021 Dec;9(12):941-942. doi: 10.1016/j.jchf.2021.09.009. JACC Heart Fail. 2021. PMID: 34857179 No abstract available.